Cover Image
市場調查報告書

腦膜炎感染疾病的開發中產品分析

Neisseria meningitidis Infections - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 293895
出版日期 內容資訊 英文 104 Pages
訂單完成後即時交付
價格
Back to Top
腦膜炎感染疾病的開發中產品分析 Neisseria meningitidis Infections - Pipeline Review, H2 2016
出版日期: 2016年10月12日 內容資訊: 英文 104 Pages
簡介

腦膜炎感染症是血液及髓膜(腦及脊髓上覆的薄膜)感染細菌的重大疾病,症狀有發燒,頸椎僵直,關節痛,噁心,意識障礙等。風險要素有年齡,抽煙,粘膜病變,人群,乾季·乾旱等天氣,沙塵暴,同時感染呼吸疾病等。

本報告提供全球各國治療腦膜炎感染疾病之開發中產品的開發情形相關分析,提供您產品開發·上市的最新趨勢,臨床實驗的各階段產品一覽,並彙整主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

  • 分析範圍

腦膜炎感染疾病概要

治療藥的開發

  • 腦膜炎感染疾病開發中產品:概要
  • 腦膜炎感染疾病開發中產品:比較分析

各企業開發中的腦膜炎感染疾病治療藥

大學/研究機關研究中的腦膜炎感染疾病治療藥

開發中產品的概要

  • 臨床實驗階段的產品
  • 初期階段的產品

腦膜炎感染疾病:企業開發中的產品

腦膜炎感染疾病:大學/研究機關研究中的產品

腦膜炎感染疾病治療藥的開發企業

  • ImmunoBiology Ltd.
  • MGB Biopharma Limited

腦膜炎感染疾病:治療藥的評估

  • 單劑治療藥的情況
  • 標的別
  • 各作用機制
  • 各投藥法
  • 各分子類型

藥物簡介

  • diphtheria + tetanus + pertussis (whole-cell) + poliomyelitis + haemophilus influenzae serotype B + hepatitis B + meningococcal serotype C (7-valent) vaccine
  • MenBioVax
  • meningococcal serotype B vaccine
  • meningococcal tetanus strain 2135 serogroup C vaccine
  • meningococcal vaccine serogroups B
  • MGBBP-3
  • neisseria meningitidis serotype B vaccine
  • neisseria meningitidis vaccine serotype B
  • TP-10

腦膜炎感染疾病治療藥:開發中產品的最新趨勢

腦膜炎感染疾病治療藥:開發暫停的產品

腦膜炎感染疾病治療藥:開發中止的產品

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8531IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Neisseria meningitidis Infections - Pipeline Review, H2 2016, provides an overview of the Neisseria meningitidis Infections (Infectious Disease) pipeline landscape.

Neisseria Meningitidis is a severe bacterial infection of the bloodstream and meninges (a thin lining covering the brain and spinal cord). Symptoms include fever, neck stiffness, joint pain, nausea, confusion and drowsiness. Risk factors include age, smoking, mucosal lesions, overcrowding, climatic conditions such as dry seasons or prolonged drought and dust storms and concomitant respiratory infections.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Neisseria meningitidis Infections - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Neisseria meningitidis Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Neisseria meningitidis Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Neisseria meningitidis Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 5, 3, 2, 3, 8 and 2 respectively for Similarly, the Universities portfolio in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages comprises 2, 2, 1, 5 and 1 molecules, respectively for Neisseria meningitidis Infections.

Neisseria meningitidis Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Neisseria meningitidis Infections (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Neisseria meningitidis Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Neisseria meningitidis Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Neisseria meningitidis Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Neisseria meningitidis Infections (Infectious Disease)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Neisseria meningitidis Infections (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Neisseria meningitidis Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Neisseria meningitidis Infections Overview
  • Therapeutics Development
    • Pipeline Products for Neisseria meningitidis Infections - Overview
    • Pipeline Products for Neisseria meningitidis Infections - Comparative Analysis
  • Neisseria meningitidis Infections - Therapeutics under Development by Companies
  • Neisseria meningitidis Infections - Therapeutics under Investigation by Universities/Institutes
  • Neisseria meningitidis Infections - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Neisseria meningitidis Infections - Products under Development by Companies
  • Neisseria meningitidis Infections - Products under Investigation by Universities/Institutes
  • Neisseria meningitidis Infections - Companies Involved in Therapeutics Development
    • Beijing Minhai Biotechnology Co., Ltd
    • Beijing Tiantan Biological Products Co., Ltd.
    • Biological E. Limited
    • China National Pharmaceutical Group Corporation
    • GlaxoSmithKline Plc
    • ImmunoBiology Limited
    • JN-International Medical Corporation
    • MGB Biopharma Limited
    • Panacea Biotec Limited
    • Pfizer Inc.
    • Sanofi Pasteur SA
    • Serum Institute of India Limited
    • Wellstat Vaccines, LLC
  • Neisseria meningitidis Infections - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + meningococcal [serotype C] + pertussis (whole cell) + poliomyelitis + tetanus) (7-valent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (meningococcal + Haemophilus influenzae [serotype B]) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (meningococcal [serotypes A, C, W-135, X, Y] (pentavalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MenBioVax - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • meningococcal (tetravalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • meningococcal [serotype B] vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • meningococcal [serotype B] vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • meningococcal [serotype B] vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • meningococcal [serotype B] vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • meningococcal [serotype B] vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • meningococcal [serotype B] vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • meningococcal [serotype B] vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • meningococcal [serotypes A, B, C, W-135, Y] (pentavalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • meningococcal [serotypes A, C, W, Y] vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • meningococcal [serotypes A, C, W-135, Y] (tetravalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • meningococcal [serotypes A, C, W-135, Y] (tetravalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • meningococcal [serotypes A, C, W-135, Y] (tetravalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • meningococcal [serotypes A, C, W-135, Y] (tetravalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • meningococcal [serotypes A, C, W-135, Y] (tetravalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • meningococcal [serotypes A, C, W-135, Y] (tetravalent) vaccine 2 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • meningococcal [serotypes A, C, W-135, Y] vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • meningococcal [serotypes A, C, W-135, Y] vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • meningococcal [serotypes A, C, W135, X, Y] vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • meningococcal [serotypes A, C, W135] vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • meningococcal [serotypes A, C] vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • meningococcal [serotypes C, Y] vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • meningococcal [strain C2135] vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • meningococcal vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • meningococcal vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • meningococcal vaccine 2 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MGBBP-3 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Neisseria meningitidis [serotype B] vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Neisseria meningitidis [serotype B] vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Nimenrix - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TP-10 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Neisseria meningitidis Infections - Dormant Projects
  • Neisseria meningitidis Infections - Discontinued Products
  • Neisseria meningitidis Infections - Product Development Milestones
    • Featured News & Press Releases
      • Sep 05, 2016: 'Real world' data shows 83 percent effectiveness for Bexsero in infants in first year of UK national meningitis B immunisation programme
      • May 20, 2016: Pfizer Announces European Medicines Agency Acceptance For Review Of Marketing Authorization Application For TRUMENBA (Meningococcal Group B Vaccine)
      • May 13, 2016: GSK's Bexsero achieves primary and secondary endpoints with reduced 3-dose schedule (2+1) in safety and immunogenicity study in infants and children
      • May 13, 2016: Pfizer Presents Results From Two Phase 3 TRUMENBA (Meningococcal Group B Vaccine) Studies At The European Society For Paediatric Infectious Diseases Meeting
      • Oct 09, 2015: Pfizer's Phase 2 Study Demonstrates Safety, Tolerability and Immunogenicity of TRUMENBA When Coadministered with Meningococcal A, C, Y and W-135 Polysaccharide Conjugate and Tetanus, Diphtheria and Pertussis Vaccines in Adolescents
      • Aug 21, 2015: Pfizer Announces Positive Topline Results Of Two Phase 3 Studies Of TRUMENBA (Meningococcal Group B Vaccine)
      • Jun 24, 2015: CDC Advisory Committee on Immunization Practices Votes to Recommend Serogroup B Meningococcal Disease Vaccination including TRUMENBA for Adolescents and Young Adults 16 through 23 Years of Age
      • Jun 24, 2015: U.S. CDC committee recommends physicians make individual decisions on the use of meningococcal group B vaccines
      • May 01, 2015: GSK launches first vaccine to prevent meningococcal disease caused by meningococcus B in Brazil
      • Mar 29, 2015: GSK statement on meningitis vaccination in the UK
      • Feb 26, 2015: CDC Advisory Committee on Immunization Practices Votes to Recommend Serogroup B Meningococcal Disease Vaccination for Persons at Increased Risk
      • Feb 24, 2015: Pfizer Announces Positive Top-line Results Of A Phase 2 Study Of TRUMENBA Co-Administered With Routine Meningococcal (A, C, Y, and W) And Tetanus, Diptheria And Pertussis Vaccines In Adolescents
      • Jan 23, 2015: FDA approves a second vaccine to prevent serogroup B meningococcal disease
      • Dec 24, 2014: Cansino Biotechnology: Meningococcal Group ACYW135 Quadrivalent Conjugate Vaccine is Approved for Clinical Trial
      • Nov 18, 2014: TRUMENBA (Meningococcal Group B Vaccine) is Now Available
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Neisseria meningitidis Infections, H2 2016
  • Number of Products under Development for Neisseria meningitidis Infections - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Neisseria meningitidis Infections - Pipeline by Beijing Minhai Biotechnology Co., Ltd, H2 2016
  • Neisseria meningitidis Infections - Pipeline by Beijing Tiantan Biological Products Co., Ltd., H2 2016
  • Neisseria meningitidis Infections - Pipeline by Biological E. Limited, H2 2016
  • Neisseria meningitidis Infections - Pipeline by China National Pharmaceutical Group Corporation, H2 2016
  • Neisseria meningitidis Infections - Pipeline by GlaxoSmithKline Plc, H2 2016
  • Neisseria meningitidis Infections - Pipeline by ImmunoBiology Limited, H2 2016
  • Neisseria meningitidis Infections - Pipeline by JN-International Medical Corporation, H2 2016
  • Neisseria meningitidis Infections - Pipeline by MGB Biopharma Limited, H2 2016
  • Neisseria meningitidis Infections - Pipeline by Panacea Biotec Limited, H2 2016
  • Neisseria meningitidis Infections - Pipeline by Pfizer Inc., H2 2016
  • Neisseria meningitidis Infections - Pipeline by Sanofi Pasteur SA, H2 2016
  • Neisseria meningitidis Infections - Pipeline by Serum Institute of India Limited, H2 2016
  • Neisseria meningitidis Infections - Pipeline by Wellstat Vaccines, LLC, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Neisseria meningitidis Infections - Dormant Projects, H2 2016
  • Neisseria meningitidis Infections - Dormant Projects (Contd..1), H2 2016
  • Neisseria meningitidis Infections - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Neisseria meningitidis Infections, H2 2016
  • Number of Products under Development for Neisseria meningitidis Infections - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top